International Quality Assurance Programme (Iqap)
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Overview of the Misuse of Drugs Act 1971
Psychoactive Substances Bill Factsheet: Overview of the Misuse of Drugs Act 1971 1. The provisions of the Psychoactive Substances Bill will build on and complement the existing legislative framework for the control of dangerous drugs as contained in the Misuse of Drugs Act 1971 (the 1971 Act). This factsheet provides an overview of the provisions of the 1971 Act. The Misuse of Drugs Act 1971 2. The 1971 Act provides the legislative framework for the regulation of “dangerous or otherwise harmful” drugs; the Act applies to the whole of the United Kingdom. The 1971 Act implements the UK’s international obligations under the United Nations Conventions for the prevention of drug misuse and trafficking, namely the Single Convention on Narcotic Drugs 19611 and the Convention on Psychotropic Substances 19712, which are complemented by the Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances 19883. 3. The 1971 Act applies to "controlled drugs". This includes substances or products specified in Schedule 2 to the Act. That Schedule divides controlled drugs into one of three Classes – A, B and C – broadly based on their relative harms, with Class A drugs considered the most harmful. Examples of each class of drug are: Class A - cocaine, methadone and opium; Class B - amphetamine, cannabis and ketamine; Class C - khat and temazepam. In addition, controlled drugs include any substance or product specified in a temporary class drug order as a drug subject to temporary control (see below). 4. The 1971 Act provides for a range of offences in relation to controlled drugs, including: • importation and exportation (section 3); • production, supply or offering to supply (section 4); • possession and possession with intent to supply (section 5); and • permitting premises to be used for certain activities, including the production or supply of a controlled drug and smoking cannabis (section 8). -
An Analytical Perspective on Determination of Free Base Nicotine in E-Liquids
Virginia Commonwealth University VCU Scholars Compass Pharmaceutics Publications Dept. of Pharmaceutics 2020 An Analytical Perspective on Determination of Free Base Nicotine in E-Liquids Vinit V. Gholap Virginia Commonwealth University Rodrigo S. Heyder Virginia Commonwealth University Leon Kosmider Medical University of Silesia Matthew S. Halquist Virginia Commonwealth University, [email protected] Follow this and additional works at: https://scholarscompass.vcu.edu/pceu_pubs Part of the Pharmacy and Pharmaceutical Sciences Commons Copyright © 2020 Vinit V. Gholap et al. -is is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Downloaded from https://scholarscompass.vcu.edu/pceu_pubs/19 This Article is brought to you for free and open access by the Dept. of Pharmaceutics at VCU Scholars Compass. It has been accepted for inclusion in Pharmaceutics Publications by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. Hindawi Journal of Analytical Methods in Chemistry Volume 2020, Article ID 6178570, 12 pages https://doi.org/10.1155/2020/6178570 Research Article An Analytical Perspective on Determination of Free Base Nicotine in E-Liquids Vinit V. Gholap ,1 Rodrigo S. Heyder,2 Leon Kosmider,3 and Matthew S. Halquist 1 1Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University, Richmond 23298, VA, USA 2Department of Pharmaceutics, Pharmaceutical Engineering, School of Pharmacy, Virginia Commonwealth University, Richmond 23298, VA, USA 3Department of General and Inorganic Chemistry, Medical University of Silesia, Katowice FOPS in Sosnowiec, Jagiellonska 4, 41-200 Sosnowiec, Poland Correspondence should be addressed to Matthew S. -
ACMD Statment of Evidence
ACMD Advisory Council on the Misuse of Drugs Chair: Professor Les Iversen Secretary: Will Reynolds 3rd Floor Seacole Building 2. Marsham Street London SW1P 4DF 020 7035 0454 Email: [email protected] Minister of State for Crime Prevention and Antisocial Behaviour Reduction, Home Office 2. Marsham Street London SW1P 4DF 23rd March 2012 Dear Minister, I am writing in response to your formal request for the Advisory Council on the Misuse of Drugs (ACMD) to provide advice on the drug methoxetamine, pursuant to section 2A of the Misuse of Drugs Act 1971 (a temporary class drug order). I have pleasure in providing the ACMD’s consideration of the evidence concerning this drug. In providing this advice I would like to convey my thanks to the Home Office for its provision of information obtained via the Drugs Early Warning System (DEWS) and the Forensic Early Warning System (FEWS). Background In September 2010 internet dealers began to advertise a new product, methoxetamine, a close chemical analogue of ketamine. It was said to mimic the psychoactive effects of ketamine but represented a legal alternative. The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) first detected this compound in the UK in September 2010, and has now received reports of its presence in many European countries. Its presence in police seizures has now been reported in samples from many different regions. There has been a rise in visits to the FRANK help site, and to the National Poisons Information Service (TOXBASE) in the past 6 months and also an increased, although small total number, of presentations of users with acute methoxetamine toxicity to hospital Emergency Departments. -
Drugs Policy in the New Programme for Government
Issue 37 Spring 2011 drugnetIRELAND Newsletter of the Alcohol and Drug Research Unit Drugs policy in the new Hearing the voices of service users programme for government As this newsletter goes to press, the government See pages 5–7. has not announced its intentions with regard to the future location of the Offi ce of the Minister for Drugs and its functions. However, the new programme for government, Government for National Recovery 2011–2016,1 contains a To have Drugnet Ireland number of actions related to drugs policy. This delivered to your desktop, article attempts to identify the implications of sign up on the NDC website these actions should they be implemented. Actions related to crime and justice www.drugsandalcohol.ie We will introduce roadside drug testing programmes to combat the problem of driving under the infl uence of drugs. The development of reliable roadside testing procedure has been a challenging issue for many > From research to policy: countries. At present the Garda Síochána, the Department of Transport and the Medical Bureau of Road Safety are collaborating in the development of a scheme to introduce US-style roadside tests the Sax Institute seminar on suspected drug drivers to accompany roadside alcohol tests. > HSE plan for drug- We will ensure that violent offenders and other serious offenders serve appropriate prison sentences while related services in 2011 at the same time switching away from prison sentences and towards less costly non-custodial options for non-violent and less serious offenders. > Update on drug-related The fi rst Bill introduced by the new Minister for Justice and Law Reform is the Criminal Justice deaths and deaths (Community Service) (Amendment) (No. -
Salts of Therapeutic Agents: Chemical, Physicochemical, and Biological Considerations
molecules Review Salts of Therapeutic Agents: Chemical, Physicochemical, and Biological Considerations Deepak Gupta 1, Deepak Bhatia 2 ID , Vivek Dave 3 ID , Vijaykumar Sutariya 4 and Sheeba Varghese Gupta 4,* 1 Department of Pharmaceutical Sciences, School of Pharmacy, Lake Erie College of Osteopathic Medicine, Bradenton, FL 34211, USA; [email protected] 2 ICPH Fairfax Bernard J. Dunn School of Pharmacy, Shenandoah University, Fairfax, VA 22031, USA; [email protected] 3 Wegmans School of Pharmacy, St. John Fisher College, Rochester, NY 14618, USA; [email protected] 4 Department of Pharmaceutical Sciences, USF College of Pharmacy, Tampa, FL 33612, USA; [email protected] * Correspondence: [email protected]; Tel.: +01-813-974-2635 Academic Editor: Peter Wipf Received: 7 June 2018; Accepted: 13 July 2018; Published: 14 July 2018 Abstract: The physicochemical and biological properties of active pharmaceutical ingredients (APIs) are greatly affected by their salt forms. The choice of a particular salt formulation is based on numerous factors such as API chemistry, intended dosage form, pharmacokinetics, and pharmacodynamics. The appropriate salt can improve the overall therapeutic and pharmaceutical effects of an API. However, the incorrect salt form can have the opposite effect, and can be quite detrimental for overall drug development. This review summarizes several criteria for choosing the appropriate salt forms, along with the effects of salt forms on the pharmaceutical properties of APIs. In addition to a comprehensive review of the selection criteria, this review also gives a brief historic perspective of the salt selection processes. Keywords: chemistry; salt; water solubility; routes of administration; physicochemical; stability; degradation 1. -
The Misuse of Drugs Act 1971 Amendment Order 2013
EXPLANATORY MEMORANDUM TO THE MISUSE OF DRUGS ACT 1971 (AMENDMENT) ORDER 2013 2013 No. 1. This explanatory memorandum has been prepared by the Home Office and is laid before Parliament by Command of Her Majesty. 2. Purpose of the instrument 2.1 This Order in Council (the “Order”) controls the following as Class B drugs under Part 2 of Schedule 2 of the Misuse of Drugs Act 1971 (the “1971 Act): (i) Synthetic cannabinoid receptor agonists (synthetic cannabinoids) ; (ii) 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexanone (commonly known as methoxetamine) and other compounds related to ketamine (Class C) and phencyclidine (Class A); and (iii) 2-((dimethylamino)methyl)-1-(3-hydroxyphenyl)cyclohexanol (commonly known as “O-desmethyltramadol”, a metabolite of the prescription only medicine, tramadol). 3. Matters of special interest to the Joint Committee on Statutory Instruments 3.1 None. 4. Legislative Context 4.1 The Misuse of Drugs Act 1971 (“the 1971 Act”) controls drugs that are “dangerous or otherwise harmful”. Schedule 2 to the 1971 Act specifies these drugs and groups them in three categories – Part 1 lists drugs known as Class A drugs, Part 2 contains Class B drugs and Part 3 lists Class C drugs. The three-tier system of classification (A, B and C) provides a framework within which criminal penalties are set with reference to the harm a drug has or is capable of causing when misused and the type of illegal activity undertaken in regard to that drug. 4.2 Section 2 of the 1971 Act enables amendments to be made to the list of drugs controlled under the Act by means of an Order in Council. -
Misuse of Drugs Regulations 2017 2 [173]
STATUTORY INSTRUMENTS. S.I. No. 173 of 2017 ———————— MISUSE OF DRUGS REGULATIONS 2017 2 [173] S.I. No. 173 of 2017 MISUSE OF DRUGS REGULATIONS 2017 ARRANGEMENT OF REGULATIONS PART 1 Preliminary and General 1. Citation and commencement. 2. Interpretation. PART 2 Issuing of Prescriptions by Registered Nurses and Registered Midwives 3. Provisions applicable to practitioners who are registered nurses or regis- tered midwives. 4. Person may refuse to supply drug if reasonable cause to believe conditions referred to in regulation 3 have not been satisfied. PART 3 Production, Supply, Importation and Exportation of Controlled Drugs 5. General prohibition. 6. Licences. 7. Administration. 8. Exemption for practitioners, pharmacists, etc. 9. Supply. PART 4 Possession of Controlled Drugs 10. General exemptions. 11. Exemption to possess butan-1,4-diol or dihydrofuran-2(3H)-one. 12. Exemption for midwives in respect of pentazocine and pethidine. 13. General authorities. PART 5 Documentation and Record-Keeping 14. Documents to be obtained by a supplier. [173] 3 15. Form of prescriptions. 16. Supply on prescription. 17. Marking of containers. 18. Documents required for export of controlled drugs. 19. Keeping of registers for drugs in Schedules 1 and 2. 20. Record-keeping in particular cases for drugs in Schedule 2. 21. Keeping of records for drugs in Schedules 3 and 4. 22. Preservation of registers, etc. 23. Preservation of records for drugs in Schedules 3, Part 1 of Schedule 4, and Schedule 5. 24. Furnishing of information with respect to controlled drugs. PART 6 Miscellaneous 25. Destruction of certain drugs. 26. Disposal of certain drugs on cessation of business. -
MDMA ('Ecstasy'): a Review of Its Harms and Classification Under the Misuse of Drugs Act 1971
MDMA (‘ecstasy’): A REVIEW OF ITS HARMS AND CLASSIFICATION UNDER THE MISUSE OF DRUGS ACT 1971 Advisory Council on the Misuse of Drugs ACMD Advisory Council on the Misuse of Drugs 3rd Floor (SW), Seacole Building 2 Marsham Street London SW1P 4DF February 2008 Rt Hon Jacqui Smith MP Home Office 2 Marsham Street London SW1P 4DF Dear Home Secretary, The Advisory Council on the Misuse of Drugs (ACMD) recently considered that a review of MDMA (‘ecstasy’) would be timely as there is a much greater body of evidence regarding the harms and misuse of MDMA since the Council last provided its advice to Ministers in 1996. I have pleasure in enclosing the Council’s report. The use of MDMA is undoubtedly harmful. I would therefore like to emphasise that the Council continues to be concerned about the widespread use of MDMA; particularly among young people. Due to its prevalence of use, MDMA is a significant public health issue and we believe that criminal justice measures will only have limited effect. You will wish to note that the Council strongly advises the promulgation of public health messages. It is of vital importance that issues of classification do not detract from messages concerning public health. Forensic evidence shows that MDMA is by far the most commonly seized of the ‘ecstasy-like’ drugs. MDMA is presently generically classified in Class A under the Misuse of Drugs Act with other ‘ecstasy-like’ drugs. The ACMD has not extended this review to other compounds within the generic classification since their use is considerably less than that of MDMA. -
9.18.19 Didactic
STIMULANTS- PART I Michael H. Baumann, Ph.D. Designer Drug Research Unit (DDRU), Intramural Research Program, NIDA, NIH Baltimore, MD 21224 Chronology of Stimulant Misuse 1. 1980s: Cocaine 2. 1990s: Ecstasy 3. Summary 2 Topics Covered for Each Substance Chemistry Formulations and Methods of Use Pharmacokinetics and Metabolism Desired and Adverse Effects Chronic and Withdrawal Effects Neurobiology Treatments 1980s: Cocaine Cocaine, a Plant-Based Alkaloid Andean Cocaine is Trafficked Globally UNODC World Drug Report, 2012 Formulations and Methods of Use Cocaine Free Base (i.e., Crack) Smoking of free base “rock” using pipes Cocaine HCl Intravenous injection of solutions using needle and syringe Intranasal snorting of powder Pharmacokinetics and Metabolism Pharmacokinetics Smoked drug reaches brain within seconds Intravenous drug reaches brain within seconds Intranasal drug reaches brain within minutes Metabolism Ester hydrolysis to benzoylecgonine Ecgonine methyl ester Cone, 1995 Rate Hypothesis of Drug Reward Smoked and Intravenous Routes Faster rate of drug entry into the brain Enhanced subjective and rewarding effects Intranasal and Oral Routes Slower rate of drug entry into the brain Reduced subjective and rewarding effects Desired Effects Enhanced Mood and Euphoria Increased Attention and Alertness Decreased Need for Sleep Appetite Suppression Sexual Arousal Adverse Effects Psychosis Tachycardia, Arrhythmias, Heart Attack Hypertension, Stroke Hyperthermia, Rhabdomyolysis Multisystem Organ Failure Tolerance- -
CREW Booklet
PSYCHOACTIVE DRUGS V2.1 12/16 SERVICE AVAILABILITY Drop-in Monday – Wednesday: 1pm – 5pm Thursday: 3pm – 7pm Friday – Saturday: 1pm – 5pm Sunday: Closed Telephone information Monday – Friday: 10am – 5pm Online information: www.mycrew.org.uk CONTACT Address | 32 Cockburn Street, Edinburgh, EH1 1PB Telephone | 0131 220 3404 Email | [email protected] Main | www.crew2000.org.uk Enterprise | www.mindaltering.co.uk Info and support | www.mycrew.org.uk Facebook | www.facebook.com/Crew2000 Twitter | www.twitter.com/Crew_2000 Instagram | www.instagram.com/Crew_2000 Psychoactive drugs have mind altering properties. They are often consumed to produce a wide range of desirable physical and psychological effects and there are hundreds of substances available. Psychoactive drugs can occur naturally (e.g. cannabis and psilocybin); be extracted from natural sources (e.g. cocaine and heroin) or produced synthetically (man-made) in a laboratory (e.g. MDMA and methamphetamine). People choose to take drugs for many reasons including relaxation, insomnia, pain relief, escapism, peer pressure and social norms, to get high, self-medication, to have fun, to lower inhibitions, to feel different, because they want to, to increase connection with others and music, to increase creativity, increase sexual arousal, curiosity, tradition, religious or spiritual beliefs, to lose/gain weight, to cope with grief, loneliness, trauma etc. People from all strata of society have the potential to consume drugs and we must avoid stereotypes. Most drug use is recreational and not recorded; however, pockets of problematic use exist in a range of settings. The use of drugs is widespread and includes not just illegal substances but alcohol, nicotine, caffeine and medicines - which many people do not consider to be drugs. -
Irish Drug Policy and Reform: a Research Report by Trinity FLAC In
Researchers Nicola O’Corrbui, Veronica Janice Bleeker, Deirbhile Kearney, Samantha Tancredi, Michael O’Shea, Lui Guiney, Elizabeth Ring, Aoife Cantrell, Yvonne McDonagh, Chloe Dalton, Serena Oster, Caoilainn McDaid, Ellen Hennessy, Aoibh Cassidy, Cormac Bergin, Blake Catriona, Katherine Byrne, Catherine Teevan, Julia Best, Siofra Carlin, Madeeha Akhtar, Kate Nolan, Adam Elebert, Eolann Davis, Rory Gavigan, Ronan McGurrin, Ross Malervy, Aoife Enright, Lucy Tann Robinson, Sophia Treacy. Editor: Celia Reynolds With thanks to: Liam Herrick, Irish Council for Civil Liberties Michelle Martyn, Irish Penal Reform Trust 1 DISCLAIMER Trinity FLAC assumes no responsibility for and gives no guarantees, undertakings or warranties concerning the accuracy, completeness or up-to-date nature of the information provided in this report and/or for any consequences of any actions taken on the basis of the information provided, legal or otherwise. The information provided in this report is not a complete source of information on all aspects of the law. Trinity FLAC takes no responsibility for any information or advice passed from a client to a third party. If you need professional or legal advice you should consult a suitably qualified person at one of our weekly clinics. If there are any questions, please contact: [email protected] 2 Trinity FLAC Irish Drug Policy and Reform Research Report Table of Contents Introduction 4 FLAC Legal Research Officer: Celia Reynolds I: Models for Drug Control 6 Nicola O’Corrbui, Deirbhile Kearney, Michael O’Shea, -
The UK Drug Classification System: Issues and Challenges
The UK Drug Classification System: issues and challenges Written evidence to the Advisory Council on the Misuse of Drugs as part of its review of the classification of MDMA (‘ecstasy’) Briefing September 2008 Kings Place 90 York Way London N1 9AG 020 7812 3790 [email protected] www.ukdpc.org.uk UKDPC is a registered charity, established to provide independent and objective analysis of drug policy and find ways to help the public and policy makers better understand the implications and options for future policy. UKDPC has been set up with support from the Esmée Fairbairn Foundation, initially for three years. Our objective is to analyse the evidence and explore options for drug policy which can improve the health, well being and safety of individuals, families and communities. Honorary President: John Varley, Group Chief Executive of Barclays Bank Commissioners: Dame Ruth Runciman (Chair): Chair of the Central & NW London NHS Foundation Trust & previously Chair of the Independent Inquiry into the Misuse of Drugs Act and member of The Advisory Council on the Misuse of Drugs Professor Baroness Haleh Afshar OBE: Professor of Politics & Women’s Studies, University of York Professor Colin Blakemore FRS: Professor of Neuroscience at the Universities of Oxford and Warwick. David Blakey CBE QPM: formerly HM Inspector of Constabulary, President of ACPO & Chief Constable of West Mercia Annette Dale-Perera : Director of Quality at the National Treatment Agency for Substance Misuse Professor the Baroness Finlay of Llandaff : Professor of Palliative Care, University of Wales & President of the Royal Society of Medicine. Daniel Finkelstein OBE: Comment Editor at The Times Jeremy Hardie CBE: Trustee of Esmée Fairbairn Foundation Professor Lord Kamlesh Patel OBE: Head of the Centre for Ethnicity & Health at University of Central Lancashire & Chairman of the Mental Health Act Commission Professor Alan Maynard: Professor of Health Economics at the University of York Adam Sampson : Chief Executive of Shelter.